Cargando…
Anlotinib affects systemic lipid metabolism and induces lipid accumulation in human lung cancer cells
BACKGROUND: Anlotinib has demonstrated encouraging clinical outcomes in the treatment of lung cancer, soft tissue sarcoma and thyroid carcinoma. Several clinical studies have shown a relationship between anlotinib treatment and the occurrence of hyperlipidemia. The fundamental mechanisms, however, a...
Autores principales: | Zhu, Zhongling, Xu, Shan, Ren, Jing, Jiang, Teng, Zhang, Cai, Yan, Zhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10464365/ https://www.ncbi.nlm.nih.gov/pubmed/37612751 http://dx.doi.org/10.1186/s12944-023-01907-y |
Ejemplares similares
-
Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways
por: Zhu, Zhongling, et al.
Publicado: (2021) -
Anlotinib suppresses lung adenocarcinoma growth via inhibiting FASN-mediated lipid metabolism
por: Shen, Juan, et al.
Publicado: (2022) -
Lysophosphatidylethanolamine Affects Lipid Accumulation and Metabolism in a Human Liver-Derived Cell Line
por: Yamamoto, Yusuke, et al.
Publicado: (2022) -
Veratrilla baillonii Franch Could Alleviate Lipid Accumulation in LO2 Cells by Regulating Oxidative, Inflammatory, and Lipid Metabolic Signaling Pathways
por: Huang, Xian-ju, et al.
Publicado: (2020) -
Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Tang, Mengqiu, et al.
Publicado: (2021)